September 2022, Vol 3, No 3

September 2022, Vol 3, No 3 — September 29, 2022
Patients with advanced biliary tract cancers (BTCs) have a poor prognosis despite systemic chemotherapy. Gemcitabine/cisplatin (GemCis) is the standard first-line systemic therapy for BTCs; however, median overall survival was only 11.7 months.
Read More

September 2022, Vol 3, No 3 — September 29, 2022
For patients with localized intrahepatic cholangiocarcinoma (iCCA), surgical resection holds curative potential for only 30% to 35% of patients due to its high rate of recurrence.
Read More

September 2022, Vol 3, No 3 — September 29, 2022
Although gemcitabine plus platinum/fluorouracil combinations are the standard first-line treatment for advanced biliary tract cancers (BTCs), the overall outcomes are suboptimal.
Read More

September 2022, Vol 3, No 3 — September 29, 2022
Results of the randomized, double-blind, global, phase 3 TOPAZ-1 trial demonstrated that the first-line chemoimmunotherapy regimen of the PD-L1 inhibitor durvalumab plus gemcitabine/cisplatin (GemCis; median follow-up, 16.8 months) significantly improved overall survival (OS) versus placebo plus GemCis (median follow-up, 15.9 months) in patients with advanced biliary tract cancers (BTCs).1
Read More

September 2022, Vol 3, No 3 — September 29, 2022
The randomized, double-blind, global, phase 3 TOPAZ-1 trial demonstrated that the first-line PD-L1 inhibitor durvalumab plus gemcitabine/cisplatin (GemCis; median follow-up, 16.8 months) as first-line treatment significantly improved overall survival (OS) versus placebo plus GemCis (median follow-up, 15.9 months) in patients with advanced biliary tract cancers (BTCs).1
Read More

September 2022, Vol 3, No 3 — September 29, 2022
Tumor-related liver failure (TRLF) is the most common cause of death in patients with metastatic intrahepatic cholangiocarcinoma (iCCA), accounting for up to 72% of deaths in patients treated with systemic therapy alone.1
Read More

September 2022, Vol 3, No 3 — September 29, 2022
Primary analysis of the pivotal, single-arm, phase 2 FOENIX-CCA2 study demonstrated that the FGFR1-4 inhibitor futibatinib as second-line treatment yielded durable objective responses in patients with intrahepatic cholangiocarcinoma (iCCA) harboring FGFR2 fusion/rearrangements.
Read More

September 2022, Vol 3, No 3 — September 28, 2022
First-line treatment options are limited to gemcitabine/cisplatin (GemCis) for patients with advanced cholangiocarcinoma (CCA).
Read More

September 2022, Vol 3, No 3 — September 28, 2022
Surgery remains the only potentially curative modality for cholangiocarcinoma (CCA) in any site of origin.
Read More

September 2022, Vol 3, No 3 — September 28, 2022
On September 2, 2022, the US Food and Drug Administration approved durvalumab in combination with gemcitabine/cisplatin for advanced biliary tract cancers (BTCs) on the basis of the TOPAZ-1 study.
Read More

Page 1 of 2


Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: